Abstract 589P
Background
Circulating tumor DNA (ctDNA) based molecular residual disease (MRD) detection has been shown to predict prognosis and guide individualized management of colorectal cancer (CRC). The landmark point is usually set at 4-12 weeks post resection in consideration of the disturbance to cell-free DNA (cfDNA) by surgery. This study aimed to evaluate the feasibility of moving the landmark point to 1-week post resection.
Methods
The study prospectively and consecutively enrolled stage I-IV CRC patients who received R0 resection. Blood samples at baseline, post-operative day (POD) 7, POD30 and subsequent every 3-6 months surveillance were collected. The MRD status of all the samples were evaluated by the Burning Rock Patient-specific pROgnostic and Potential tHErapeutic marker Tracking (brPROPHETTM) approach. The cfDNA level, mean tumor mutant (MTM), positive predictive value (PPV) and negative predictive value (NPV) were compared between POD7 and POD30.
Results
In total, 164 eligible patients were enrolled. The median follow-up duration was 311 days (95% CI, 296-351) up to date. The brPROPHET displayed a high sensitivity of 95.1% (155/163) for detecting ctDNA preoperatively, with 88.5%, 96.1%, 96.2%, 100% in stage I to IV, respectively. Post-resection ctDNA positive rates were decreased to 15.2% (25/164) at POD7 and 12.8% (21/164) at POD30. The cfDNA levels of POD7 were significantly higher than those of baseline and POD30 (P<0.001). However, the MTMs were similar between POD7 and POD30 (P = 0.55). The accordance between POD7 and POD30 was 91.5% (150/164). For 6-month recurrence, the PPV was 13.6% vs 15.8% for POD7 and POD30, respectively, with NPV of 100% vs 98.2%. Of the 25 ctDNA positive patients at POD7, 9 turned negative at POD30 and had significantly lower ctDNA levels at POD7 than those who didn’t (P<0.001). Patients with decreased ctDNA from POD7 to POD30 had a higher ctDNA clearance rate during surveillance than those without decreased ctDNA (100% vs 30%, P = 0.02).
Conclusions
The performance of ctDNA detection in POD7 and POD30 was similar. Shift of the landmark time to 1-week post resection may provide an easier way to evaluate MRD status for prognostic stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
538P - Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
Presenter: Giulia Pretelli
Session: Poster session 10
539P - Epidemiology and prognostic factors of lung cancer and brain metastases: A 10-year retrospective population cohort study in Girona, Spain
Presenter: Eduard Teixidor Vilà
Session: Poster session 10
540P - Impact of adjuvant radiotherapy (ART) on survival time in patients with hemangiopericytoma (HPC): A population study
Presenter: Tala Alshwayyat
Session: Poster session 10
541P - A multicenter study evaluating the clinical and molecular characteristics of adult patients with diffuse midline and non-midline K27M altered gliomas
Presenter: Manuel Mazariegos Rubi
Session: Poster session 10
542P - Drug screening in Li-Fraumeni syndrome brain tumor models
Presenter: Anna Kolodziejczak
Session: Poster session 10
543P - Bevacizumab and hydroxyurea treatment in grade 2 and 3 meningioma: A monocentric experience
Presenter: Giulia Cerretti
Session: Poster session 10
544P - Clinical and molecular features of primary central nervous system tumor with Lynch syndrome
Presenter: Nan Liu
Session: Poster session 10
545P - Antibody-fragment based immunotherapeutic approaches for medulloblastoma and rhabdomyosarcoma
Presenter: Judith Niesen
Session: Poster session 10
546P - Early urinary potassium level is predictive of delayed methotrexate (MTX) elimination in patients with primary central nervous system lymphoma (PCNSL)
Presenter: Alexandre Bertucci
Session: Poster session 10
547P - Clinicopathological and molecular study of embryonal tumours with multilayered rosettes
Presenter: Lianghong Teng
Session: Poster session 10